The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Immunopathogenesis and treatment of cytokine storm in COVID-19
Open accessAbstract
Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper-inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine storm refers to a set of clinical conditions caused by excessive immune reactions and has been recognized as a leading cause of severe COVID-19. While comparisons have been made between COVID-19 cytokine storm and other kinds of cytokine storm such as hemophagocytic lymphohistiocytosis and cytokine release syndrome, the pathogenesis of cytokine storm has not been clearly elucidated yet. Recent studies have shown that impaired response of type-1 IFNs in early stage of COVID-19 infection played a major role in the development of cytokine storm, and various cytokines such as IL-6 and IL-1 were involved in severe COVID-19. Furthermore, many clinical evidences have indicated the importance of anti-inflammatory therapy in severe COVID-19. Several approaches are currently being used to treat the observed cytokine storm associated with COVID-19, and expectations are especially high for new cytokine-targeted therapies, such as tocilizumab, anakinra, and baricitinib. Although a number of studies have been conducted on anti-inflammatory treatments for severe COVID-19, no specific recommendations have been made on which drugs should be used for which patients and when. In this review, we provide an overview of cytokine storm in COVID-19 and treatments currently being used to address it. In addition, we discuss the potential therapeutic role of extracorporeal cytokine removal to treat the cytokine storm associated with COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
Rothan, H. A., & Byrareddy, S. N. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102433 · Cited by 5,840
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
Ye, Q., Wang, B., & Mao, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.037 · Cited by 2,761
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007016 · Cited by 2,737
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Cummings, M. J., Baldwin, M. R., Abrams, D., Jacobson, S. D., Meyer, B. J., Balough, E. M., Aaron, J. G., Claassen, J., Rabbani, L. E., Hastie, J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31189-2 · Cited by 2,212
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 4×
“In addition, acute increases in various cytokines were also noted in the early phase: tumor necrosis factor-alpha (TNF-α) was observed within an hour, followed by IL-1 [8].”
BackgroundInfluentialClinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Russell, C. D., Millar, J. E., & Baillie, J. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30317-2 · Cited by 2,008
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654
Ronco, C., Bellomo, R., Homel, P., Brendolan, A., Dan, M., Piccinni, P., & La Greca, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02430-2 · Cited by 1,594
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456
Remdesivir for the Treatment of Covid-19 — Preliminary Report
(2020) · New England Journal of Medicine · doi:10.1056/nejmc2022236 · Cited by 1,396
Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108393 · Cited by 1,266
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
Herold, T., Jurinovic, V., Arnreich, C., Lipworth, B. J., Hellmuth, J. C., von Bergwelt-Baildon, M., Klein, M., & Weinberger, T. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.008 · Cited by 1,161
Leng, Z., Zhu, R., Hou, W., Feng, Y., Yang, Y., Han, Q., Shan, G., Meng, F., Du, D., Wang, S., et al. (2020) · Aging and disease · doi:10.14336/ad.2020.0228 · Cited by 1,147
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults
La Rosée, P., Horne, A., Hines, M., von Bahr Greenwood, T., Machowicz, R., Berliner, N., Birndt, S., Gil-Herrera, J., Girschikofsky, M., Jordan, M. B., et al. (2019) · Blood · doi:10.1182/blood.2018894618 · Cited by 1,108
Convalescent plasma as a potential therapy for COVID-19
Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038
Cavalli, G., De Luca, G., Campochiaro, C., Della-Torre, E., Ripa, M., Canetti, D., Oltolini, C., Castiglioni, B., Tassan Din, C., Boffini, N., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30127-2 · Cited by 970
Pascual, V., Allantaz, F., Arce, E., Punaro, M., & Banchereau, J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050473 · Cited by 922
Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867
Initiative, T. C.-1. H. G. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-0636-6 · Cited by 763
The cytokine storm of severe influenza and development of immunomodulatory therapy
Liu, Q., Zhou, Y.-H., & Yang, Z.-Q. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.74 · Cited by 716
Jordan, M. B., Hildeman, D., Kappler, J., & Marrack, P. (2004) · Blood · doi:10.1182/blood-2003-10-3413 · Cited by 712
Anakinra for severe forms of COVID-19: a cohort study
Huet, T., Beaussier, H., Voisin, O., Jouveshomme, S., Dauriat, G., Lazareth, I., Sacco, E., Naccache, J.-M., Bézie, Y., Laplanche, S., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30164-8 · Cited by 643
On the use of corticosteroids for 2019-nCoV pneumonia
Shang, L., Zhao, J., Hu, Y., Du, R., & Cao, B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30361-5 · Cited by 604
Schwartz, J., Winters, J. L., Padmanabhan, A., Balogun, R. A., Delaney, M., Linenberger, M. L., Szczepiorkowski, Z. M., Williams, M. E., Wu, Y., & Shaz, B. H. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21276 · Cited by 603
Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial
Busund, R., Koukline, V., Utrobin, U., & Nedashkovsky, E. (2002) · Intensive Care Medicine · doi:10.1007/s00134-002-1410-7 · Cited by 562
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
Feldmann, M., Maini, R. N., Woody, J. N., Holgate, S. T., Winter, G., Rowland, M., Richards, D., & Hussell, T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30858-8 · Cited by 536
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
Locatelli, F., Jordan, M. B., Allen, C., Cesaro, S., Rizzari, C., Rao, A., Degar, B., Garrington, T. P., Sevilla, J., Putti, M.-C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911326 · Cited by 534
Hypercytokinemia in familial hemophagocytic lymphohistiocytosis
Henter, J., Elinder, G., Soder, O., Hansson, M., Andersson, B., & Andersson, U. (1991) · Blood · doi:10.1182/blood.v78.11.2918.2918 · Cited by 505
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
Somers, E. C., Eschenauer, G. A., Troost, J. P., Golob, J. L., Gandhi, T. N., Wang, L., Zhou, N., Petty, L. A., Baang, J. H., Dillman, N. O., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa954 · Cited by 497
Cao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.019 · Cited by 456
COVID-19 infection and rheumatoid arthritis: Faraway, so close
Favalli, E. G., Ingegnoli, F., De Lucia, O., Cincinelli, G., Cimaz, R., & Caporali, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102523 · Cited by 454
Dysregulation of type I interferon responses in COVID-19
Acharya, D., Liu, G., & Gack, M. U. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0346-x · Cited by 454
Interferon-α2b Treatment for COVID-19
Zhou, Q., Chen, V., Shannon, C. P., Wei, X.-S., Xiang, X., Wang, X., Wang, Z.-H., Tebbutt, S. J., Kollmann, T. R., & Fish, E. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01061 · Cited by 417
Campochiaro, C., Della-Torre, E., Cavalli, G., De Luca, G., Ripa, M., Boffini, N., Tomelleri, A., Baldissera, E., Rovere-Querini, P., Ruggeri, A., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.05.021 · Cited by 394
Deftereos, S. G., Giannopoulos, G., Vrachatis, D. A., Siasos, G. D., Giotaki, S. G., Gargalianos, P., Metallidis, S., Sianos, G., Baltagiannis, S., Panagopoulos, P., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13136 · Cited by 387
Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
Behrens, E. M., & Koretzky, G. A. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40071 · Cited by 304
Zheng, B.-J., Chan, K.-W., Lin, Y.-P., Zhao, G.-Y., Chan, C., Zhang, H.-J., Chen, H.-L., Wong, S. S. Y., Lau, S. K. P., Woo, P. C. Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711942105 · Cited by 302
Convalescent Plasma to Treat COVID-19: Possibilities and Challenges
Roback, J. D., & Guarner, J. (2020) · JAMA · doi:10.1001/jama.2020.4940 · Cited by 299
The mechanisms of action of plasma exchange
Reeves, H. M., & Winters, J. L. (2013) · British Journal of Haematology · doi:10.1111/bjh.12629 · Cited by 297
Anakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome
Mazodier, K. (2005) · Blood · doi:10.1182/blood-2005-05-1980 · Cited by 290
Miettunen, P. M., Narendran, A., Jayanthan, A., Behrens, E. M., & Cron, R. Q. (2011) · Rheumatology · doi:10.1093/rheumatology/keq218 · Cited by 284
Type I IFN immunoprofiling in COVID-19 patients
Trouillet-Assant, S., Viel, S., Gaymard, A., Pons, S., Richard, J.-C., Perret, M., Villard, M., Brengel-Pesce, K., Lina, B., Mezidi, M., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.029 · Cited by 265
Li, H., Chen, C., Hu, F., Wang, J., Zhao, Q., Gale, R. P., & Liang, Y. (2020) · Leukemia · doi:10.1038/s41375-020-0848-3 · Cited by 265
Carter, S. J., Tattersall, R. S., & Ramanan, A. V. (2019) · Rheumatology · doi:10.1093/rheumatology/key006 · Cited by 259
Jenkins, M. R., Rudd-Schmidt, J. A., Lopez, J. A., Ramsbottom, K. M., Mannering, S. I., Andrews, D. M., Voskoboinik, I., & Trapani, J. A. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140964 · Cited by 258
Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1.
Ferrara, J. L., Abhyankar, S., & Gilliland, D. G. (1993) · PubMed · Cited by 249
Vastert, S. J., van Wijk, R., D’Urbano, L. E., de Vooght, K. M. K., de Jager, W., Ravelli, A., Magni-Manzoni, S., Insalaco, A., Cortis, E., van Solinge, W. W., et al. (2010) · Rheumatology · doi:10.1093/rheumatology/kep418 · Cited by 231
Autoinflammation and autoimmunity: Bridging the divide
Doria, A., Zen, M., Bettio, S., Gatto, M., Bassi, N., Nalotto, L., Ghirardello, A., Iaccarino, L., & Punzi, L. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.07.018 · Cited by 225
Continuous plasmafiltration in sepsis syndrome
Reeves, J. H., Butt, W. W., Shann, F., Layton, J. E., Stewart, A., Waring, P. M., & Presneill, J. J. (1999) · Critical Care Medicine · doi:10.1097/00003246-199910000-00003 · Cited by 221
Pathogenesis and treatment of cytokine storm in COVID-19
SOY, M., KESER, G., & ATAGÜNDÜZ, P. (2021) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-2105-37 · Cited by 210
Nguyen, T. C., Han, Y. Y., Kiss, J. E., Hall, M. W., Hassett, A. C., Jaffe, R., Orr, R. A., Janosky, J., & Carcillo, J. A. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318186aa49 · Cited by 204
Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH
Hayden, A., Lin, M., Park, S., Pudek, M., Schneider, M., Jordan, M. B., Mattman, A., & Chen, L. Y. C. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017012310 · Cited by 201
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19
Seif, F., Aazami, H., Khoshmirsafa, M., Kamali, M., Mohsenzadegan, M., Pornour, M., & Mansouri, D. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000508247 · Cited by 197
Cytokine removal in human septic shock: Where are we and where are we going?
Honore, P. M., Hoste, E., Molnár, Z., Jacobs, R., Joannes-Boyau, O., Malbrain, M. L. N. G., & Forni, L. G. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0530-y · Cited by 192
Demirkol, D., Yildizdas, D., Bayrakci, B., Karapinar, B., Kendirli, T., Koroglu, T. F., Dursun, O., Erkek, N., Gedik, H., Citak, A., et al. (2012) · Critical Care · doi:10.1186/cc11256 · Cited by 190
Similar but not the same: Differential diagnosis of HLH and sepsis
Machowicz, R., Janka, G., & Wiktor-Jedrzejczak, W. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.023 · Cited by 182
Rimmer, E., Houston, B. L., Kumar, A., Abou-Setta, A. M., Friesen, C., Marshall, J. C., Rock, G., Turgeon, A. F., Cook, D. J., Houston, D. S., et al. (2014) · Critical Care · doi:10.1186/s13054-014-0699-2 · Cited by 181
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes
England, J. T., Abdulla, A., Biggs, C. M., Lee, A. Y. Y., Hay, K. A., Hoiland, R. L., Wellington, C. L., Sekhon, M., Jamal, S., Shojania, K., et al. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100707 · Cited by 177
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
Cantini, F., Niccoli, L., Nannini, C., Matarrese, D., Natale, M. E. D., Lotti, P., Aquilini, D., Landini, G., Cimolato, B., Pietro, M. A. D., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.06.052 · Cited by 174
Ma, J., Xia, P., Zhou, Y., Liu, Z., Zhou, X., Wang, J., Li, T., Yan, X., Chen, L., Zhang, S., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108408 · Cited by 171
Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis
Vallurupalli, M., & Berliner, N. (2019) · Blood · doi:10.1182/blood.2019002289 · Cited by 170
Diurnal Variation of Circulating Interleukin-6 in Humans: A Meta-Analysis
Nilsonne, G., Lekander, M., Åkerstedt, T., Axelsson, J., & Ingre, M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0165799 · Cited by 166
Knaup, H., Stahl, K., Schmidt, B. M. W., Idowu, T. O., Busch, M., Wiesner, O., Welte, T., Haller, H., Kielstein, J. T., Hoeper, M. M., et al. (2018) · Critical Care · doi:10.1186/s13054-018-2220-9 · Cited by 165
A Novel TNF-α-Targeting Aptamer for TNF-α-Mediated Acute Lung Injury and Acute Liver Failure
Lai, W., Wang, J.-W., Huang, B.-T., Lin, E. P.-Y., & Yang, P. (2019) · Theranostics · doi:10.7150/thno.30972 · Cited by 147
Toxicity management for patients receiving novel T-cell engaging therapies
Barrett, D. M., Teachey, D. T., & Grupp, S. A. (2013) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000043 · Cited by 144
Plasmapheresis treatment in COVID-19–related autoimmune meningoencephalitis: Case series
Doğan, L., Kaya, D., Sarıkaya, Z. T., Zengin, R., Dinçer, A., Akıncı, İ. Ö., & Afşar, N. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.05.022 · Cited by 142
Wulffraat, N. M. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg074 · Cited by 140
Therapeutic plasma exchange in adults with severe COVID-19 infection
Khamis, F. A., Al-Zakwani, I. S., Hashmi, S., Dowaiki, S. A., Bahrani, M. A., Pandak, N., Khalili, H. A., & Memish, Z. A. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.06.064 · Cited by 140
Clark, M. A., Plank, L. D., Connolly, A. B., Streat, S., Hill, A. A. V., Gupta, R., Monk, D. N., Shenkin, A., & Hill, G. L. (1998) · Critical Care Medicine · doi:10.1097/00003246-199810000-00016 · Cited by 126
Meng, Z., Wang, T., Chen, L., Chen, X., Li, L., Qin, X., Li, H., & Luo, J. D. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666210429083050 · Cited by 126
Dhawan, G., Kapoor, R., Dhawan, R., Singh, R., Monga, B., Giordano, J., & Calabrese, E. J. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.05.002 · Cited by 124
The Rheumatologist’s Role in COVID-19
Cron, R. Q., & Chatham, W. W. (2020) · The Journal of Rheumatology · doi:10.3899/jrheum.200334 · Cited by 123
Marsolais, D., Hahm, B., Walsh, K. B., Edelmann, K. H., McGavern, D., Hatta, Y., Kawaoka, Y., Rosen, H., & Oldstone, M. B. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812689106 · Cited by 122
Plasma exchange as rescue therapy in multiple organ failure including acute renal failure*
Stegmayr, B. G., Banga, R., Berggren, L., Norda, R., Rydvall, A., & Vikerfors, T. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000064742.00981.14 · Cited by 111
Shi, H., Zhou, C., He, P., Huang, S., Duan, Y., Wang, X., Lin, K., Chao Hui, Z. H. O. U., Zhang, X., & Zha, Y. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105974 · Cited by 111
Lounder, D. T., Bin, Q., de Min, C., & Jordan, M. B. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018025858 · Cited by 108
An Overview of Hemophagocytic Lymphohistiocytosis
Esteban, Y., de Jong, J. L. O., & Tesher, M. S. (2017) · Pediatric Annals · doi:10.3928/19382359-20170717-01 · Cited by 98
Current and Future Developments in the Treatment of Virus-Induced Hypercytokinemia
Wong, J. P., Viswanathan, S., Wang, M., Sun, L.-Q., Clark, G. C., & D’Elia, R. V. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0181 · Cited by 90
Oldstone, M. B. A., & Rosen, H. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-05879-5_6 · Cited by 85
Stahl, K., Schmidt, J. J., Seeliger, B., Schmidt, B. M. W., Welte, T., Haller, H. G., Hoeper, M. M., Budde, U., Bode, C., & David, S. (2020) · Critical Care · doi:10.1186/s13054-020-2799-5 · Cited by 83
Patel, P., Nandwani, V., Vanchiere, J. A., Conrad, S. A., & Scott, L. K. (2010) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0b013e3181e2a569 · Cited by 82
The calm after the cytokine storm: lessons from the TGN1412 trial
St. Clair, E. W. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35382 · Cited by 79
Yang, S.-L., Xu, X., Tang, Y., Song, H., Xu, W., Zhao, F., & Shen, D. (2016) · Cytokine · doi:10.1016/j.cyto.2016.05.022 · Cited by 66
Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?
Deftereos, S. G., Γιαννόπουλος, Γ., Vrachatis, D. A., Siasos, G., Giotaki, S. G., CLEMAN, M. W., Dangas, G., & Stefanadis, C. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa033 · Cited by 60
Altara, R., Manca, M., Hermans, K. C. M., Daskalopoulos, E. P., Rocca, H. B., Hermans, R. J. J., Struijker-Boudier, H. A. J., & Blankesteijn, M. W. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0477-1 · Cited by 55
Liu, J., Wan, M., Lyon, C. J., & Hu, Y. (2020) · Theranostics · doi:10.7150/thno.47982 · Cited by 55
Keith, P. D., Day, M. S., Choe, C. H., Perkins, L., Moyer, L., Hays, E., French, M., Hewitt, K., Gravel, G., Guffey, A., et al. (2020) · SAGE Open Medical Case Reports · doi:10.1177/2050313x20933473 · Cited by 53
Cao, J., Zheng, Y., Luo, Z., Mei, Z., Yao, Y., Liu, Z., Liang, C., Yang, H., Song, Y., Yu, K., et al. (2020) · Theranostics · doi:10.7150/thno.47980 · Cited by 51
Plasma exchange in critically ill COVID-19 patients
Morath, C. P., Weigand, M. A., Zeier, M., Speer, C., Tiwari‐Heckler, S., & Merle, U. (2020) · Critical Care · doi:10.1186/s13054-020-03171-3 · Cited by 48
A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats
Müller, N., van den Brandt, J., Odoardi, F., Tischner, D., Herath, J., Flügel, A., & Reichardt, H. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32698 · Cited by 46
Lee, K. H., Yoon, S., Jeong, G. H., Kim, J. Y., Han, Y. J., Hong, S. H., Ryu, S., Kim, J. S., Lee, J. Y., Yang, J. W., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082392 · Cited by 42
Self-citationHoiland, R. L., Stukas, S. K., Cooper, J. G., Thiara, S., Chen, L. Y. C., Biggs, C. M., Hay, K. A., Lee, A. Y. Y., Shojania, K., Abdulla, A., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16961 · Cited by 39
Techniques of extracorporeal cytokine removal: a systematic review of human studies
Atan, R., Crosbie, D., & Bellomo, R. (2013) · Renal Failure · doi:10.3109/0886022x.2013.815089 · Cited by 37
Maeshima, K., Ishii, K., Iwakura, M., Akamine, M., Hamasaki, H., Abe, I., Haranaka, M., Tatsukawa, H., & Yoshimatsu, H. (2011) · Modern Rheumatology · doi:10.3109/s10165-011-0477-9 · Cited by 34
Lorenz, G., Schul, L., Schraml, F., Riedhammer, K. M., Einwächter, H., Verbeek, M., Slotta‐Huspenina, J., Schmaderer, C., Küchle, C., Heemann, U. W., et al. (2020) · Lupus · doi:10.1177/0961203320901594 · Cited by 21
Pathogenesis of multi-organic failure in autoimmune diseases
Amaral, M., & Alves, J. D. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.01.009 · Cited by 13
Emerging evidence of myocardial injury in COVID-19: A path through the smoke
Tersalvi, G., Veronese, G., & Winterton, D. (2020) · Theranostics · doi:10.7150/thno.50788 · Cited by 8
Metadata
- Authors
- Kim, J. S., Lee, J. Y., Yang, J. W., Lee, K. H., Effenberger, M., Szpirt, W., Kronbichler, A., & Shin, J. I.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2021
- Volume
- 11
- Issue
- 1
- Pages
- 316-329
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W3095024243
- Cited by
- 463
- References
- 113
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.